How to transition patients to community-based bispecific antibody therapy
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
How to transition patients to community-based bispecific antibody therapy
-
ナレーター：
-
著者：
The Multiple Myeloma Hub spoke with Shaji Kumar, Mayo Clinic, Rochester, US. We asked about transitioning patients to community-based bispecific antibody therapy.
In this interview, Kumar discusses practical considerations for transitioning bispecific antibody therapy to community-based practice in patients with multiple myeloma. Kumar outlines strategies for monitoring and managing treatment-related toxicities, including cytokine release syndrome, neurological toxicities, cytopenias, and infections. Kumar also discusses patient education, supportive care, and the evolving role of less frequent and subcutaneous bispecific antibody administration in facilitating community-based treatment.
Intended for healthcare professionals. This educational resource is independently supported by Johnson & Johnson. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.
Hosted on Acast. See acast.com/privacy for more information.